Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nehal J Lakhani

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Current Drug Metabolism|December 20, 2003
Pharmacogenetics of estrogen metabolism and transport in relation to cancerNehal J Lakhani, Jürgen Venitz, William D Figg, et al.
Pharmacotherapy|February 18, 2003
2-Methoxyestradiol, a promising anticancer agentNehal J Lakhani, Mohamadi A Sarkar, Jurgen Venitz, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 3, 2004
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detectionNehal J Lakhani, Alex Sparreboom, William L Dahut, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2021
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell MalignanciesWael Harb, Nehal J Lakhani, Richard Messmann, et al.
Rapid Communications in Mass Spectrometry : RCM|April 9, 2005
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometryNehal J Lakhani, Erin R Lepper, Alex Sparreboom, et al.
Investigational New Drugs|September 14, 2024
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumorsNehal J Lakhani, Howard Burris, Wilson H Miller, et al.
Journal of Pharmaceutical Sciences|January 26, 2007
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiolNehal J Lakhani, Alex Sparreboom, Xia Xu, et al.
Cancer Metastasis Reviews|October 29, 2002
Antiangiogenesis therapeutic strategies in prostate cancerGordon R Macpherson, Sylvia S W Ng, Nehal J Lakhani, et al.
The Oncologist|September 24, 2025
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trialSarina A Piha-Paul, Justin A Call, Alexander I Spira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2023
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J Lakhani, Drew Rasco, Hengbang Wang, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Current Drug Metabolism|December 20, 2003
Pharmacogenetics of estrogen metabolism and transport in relation to cancerNehal J Lakhani, Jürgen Venitz, William D Figg, et al.
Pharmacotherapy|February 18, 2003
2-Methoxyestradiol, a promising anticancer agentNehal J Lakhani, Mohamadi A Sarkar, Jurgen Venitz, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 3, 2004
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detectionNehal J Lakhani, Alex Sparreboom, William L Dahut, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 21, 2021
A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell MalignanciesWael Harb, Nehal J Lakhani, Richard Messmann, et al.
Rapid Communications in Mass Spectrometry : RCM|April 9, 2005
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometryNehal J Lakhani, Erin R Lepper, Alex Sparreboom, et al.
Investigational New Drugs|September 14, 2024
A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumorsNehal J Lakhani, Howard Burris, Wilson H Miller, et al.
Journal of Pharmaceutical Sciences|January 26, 2007
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiolNehal J Lakhani, Alex Sparreboom, Xia Xu, et al.
Cancer Metastasis Reviews|October 29, 2002
Antiangiogenesis therapeutic strategies in prostate cancerGordon R Macpherson, Sylvia S W Ng, Nehal J Lakhani, et al.
The Oncologist|September 24, 2025
Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trialSarina A Piha-Paul, Justin A Call, Alexander I Spira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2023
First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsNehal J Lakhani, Drew Rasco, Hengbang Wang, et al.
Pageof 3